Microbiome products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46% <Roots Analysis>

Roots Analysis has done a detailed study on Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 300+ page report, which features 140+ figures and 125+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

 

Key Market Insights

• The microbiome therapies pipeline features 260 drugs under evaluation across different phases of development; contract service providers have become an integral part of the supply chain owing to their technical expertise.
• Presently, over 25 firms across the globe claim to possess the required know-how and infrastructure to offer contract manufacturing services for live biotherapeutic products and microbiome therapies
• The market is fragmented, featuring the presence of established players and mid-sized firms across different global regions, with capabilities to manufacture aerobic and / or anaerobic strains, at varying scales of operation
• Most of the installed, global live biotherapeutic contract manufacturing capacity presently belongs to dedicated large and mid-sized CMOs, accounting for over 90% of what is available across various geographies
• Future growth of the market is likely to be driven by increased demand for these therapeutics; we expect the service-based revenues to grow at an annualized rate of over 46% in the coming decade
• In the long-term, the projected market opportunity is anticipated to be well distributed across different types of formulations, sizes of contract service providers and geographical regions

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

 

Table of Contents

 

1.         PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1.       Chapter Overview

3.2.       Concept of Human Microbiota and Microbiome

3.3.       Overview of Gut Flora

3.2.3.    Role of Gut Flora in Healthy Individuals

3.2.4.    Factors Affecting Human Gut Flora

 

3.4.       The Human Microbiome Project (HMP)

3.5.       Overview of Microbiome Therapies

3.5.1.    Types of Microbiome Therapies

3.5.1.1. Probiotics

3.5.1.2. Prebiotics

 

3.5.2.    Applications of Microbiome Therapies

3.5.3.    Microbiome Therapies Supply Chain

 

3.6.       Microbiome-based Product Manufacturing

3.6.1.    Key Steps Involved

3.6.2.    Associated Challenges

3.6.3.    Role of Contract Manufacturing Organizations (CMOs)

3.6.4.    Demand for Contract Manufacturing Services

 

3.7.       Key Considerations for Selecting a Suitable CMO Partner

 

4.         MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       CMOs Offering Contract Manufacturing for Microbiome Therapeutics: List of Companies

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Scale of Operation

4.2.4.    Analysis by Location of Headquarters

4.2.5.    Analysis by Type of Service Offered

4.2.6.    Analysis by Type of Product Manufactured

4.2.7.    Analysis by Type of Drug Molecule

4.2.8.    Analysis by Type of Fermentation Required

4.2.9.    Analysis by Type of Formulation

4.2.10.  Analysis by Type of Primary Packaging Used

4.2.11. Analysis by Number of Manufacturing Facilities

4.2.12. Analysis by Location of Manufacturing Facilities

4.2.13. Analysis by Type of Regulatory Certifications / Accreditations

 

4.3.       Microbiome Therapeutics In-House Manufacturers: List of Companies

4.3.1.    Analysis by Year of Establishment

4.3.2.    Analysis by Company Size

4.3.3.    Analysis by Scale of Operation

4.3.4.    Analysis by Location of Headquarters

4.3.5.    Analysis by Location of Manufacturing Facilities

5.         COMPANY PROFILES

5.1.       Chapter Overview

5.2.       CMOs Headquartered in North America

5.2.1.    Capsugel

5.2.1.1. Company Overview

5.2.1.2. Microbiome-Related Service Portfolio

5.2.1.3. Facilities Dedicated to Microbiome Manufacturing

5.2.1.4. Recent Developments and Future Outlook

 

5.2.2.    Paragon Bioservices

5.2.2.1. Company Overview

5.2.2.2. Microbiome-Related Service Portfolio

5.2.2.3. Facilities Dedicated to Microbiome Manufacturing

5.2.2.4. Recent Developments and Future Outlook

 

5.2.3.    UAS Labs

5.2.3.1. Company Overview

5.2.3.2. Microbiome-Related Service Portfolio

5.2.3.3. Facilities Dedicated to Microbiome Manufacturing

5.2.3.4. Recent Developments and Future Outlook

 

5.3.       CMOs Headquartered in Europe

5.3.1.    Biose

5.3.1.1. Company Overview

5.3.1.2. Microbiome-Related Service Portfolio

5.3.1.3. Facilities Dedicated to Microbiome Manufacturing

5.3.1.4. Recent Developments and Future Outlook

 

5.3.2.    Cobra Biologics

5.3.2.1. Company Overview

5.3.2.2. Financial Information

5.3.2.3. Microbiome-Related Service Portfolio

5.3.2.4. Facilities Dedicated to Microbiome Manufacturing

5.3.2.5. Recent Developments and Future Outlook

 

5.3.3.    Cerbios

5.3.3.1. Company Overview

5.3.3.2. Microbiome-Related Service Portfolio

5.3.3.3. Facilities Dedicated to Microbiome Manufacturing

5.3.3.4. Recent Developments and Future Outlook

 

5.3.4.    Inpac Probiotics

5.3.4.1. Company Overview

5.3.4.2. Microbiome-Related Service Portfolio

5.3.4.3. Facilities Dedicated to Microbiome Manufacturing

5.4.       CMOs Headquartered in Asia-Pacific and Rest of the World

5.4.1.    BJP Laboratories

5.4.1.1. Company Overview

5.4.1.2. Microbiome-Related Service Portfolio

5.4.1.3. Facilities Dedicated to Microbiome Manufacturing

 

6.         REGIONAL CAPABILITY ANALYSIS

6.1.       Chapter Overview

6.2.       Key Assumptions and Methodology

6.3.       Regional Capability Analysis: Microbiome Contract Manufacturers in North America

6.4.       Regional Capability Analysis: Microbiome Contract Manufacturers in Europe

6.5.       Regional Capability Analysis: Microbiome Contract Manufacturers in Asia-Pacific and Rest of the World

6.6.       Concluding Remarks

                       

7.         LIKELY PARTNER ANALYSIS

7.1.       Chapter Overview

7.2.       Scope and Methodology

7.3.       Potential Strategic Partners for Microbiome Contract Manufacturers

7.3.1.    Opportunities in North America

7.3.2.    Opportunities in Europe and Asia-Pacific

 

8.         CLINICAL TRIAL ANALYSIS

8.1.       Chapter Overview

8.2.       Scope and Methodology

8.3.       Clinical Trial Analysis (Industry Players)

8.3.1.    Analysis by Trial Registration Year

8.3.2.    Analysis by Trial Phase

8.3.3.    Analysis by Trial Recruitment Status

8.3.4.    Analysis by Trial Registration Year and Recruitment Status

8.3.5.    Analysis by Trial Registration Year and Number of Patients Enrolled

8.3.6.    Analysis by Study Design

8.3.7.    Analysis by Trial Focus

8.3.8.    Analysis by Trial Phase and Type of Intervention Model

8.3.9.    Analysis by Sponsor / Collaborator

8.3.10. Analysis by Type of Organization

8.3.11.  Popular Therapeutic Areas: Analysis by Number of Clinical Trials and Registration Year

8.3.12. Geographical Analysis by Number of Clinical Trials

8.3.13.  Geographical Analysis by Trial Recruitment Status

 

8.4.       Clinical Trial Analysis (Non-Industry Players)

8.4.1.    Analysis by Trial Registration Year

8.4.2.    Analysis by Trial Phase

8.4.3.    Analysis by Trial Recruitment Status

8.4.4.    Analysis by Trial Registration Year and Recruitment Status

8.4.5.    Analysis by Trial Registration Year and Number of Patients Enrolled

8.4.6.    Analysis by Study Design

8.4.7.    Analysis by Trial Focus

8.4.8.    Analysis by Trial Phase and Type of Intervention Model

8.4.9.    Analysis by Sponsor / Collaborator

8.4.10. Analysis by Type of Organization

8.4.11.  Popular Therapeutic Areas: Analysis by Number of Clinical Trials and Registration Year

8.4.12. Geographical Analysis by Number of Clinical Trials

8.4.13.  Geographical Analysis by Trial Recruitment Status

 

9. &nb